Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy

Wisit Cheungpasitporn, Stephen L. Kopecky, Ulrich Specks, Kharmen Bharucha, Fernando Custodio Fervenza

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Rituximab is an anti-CD20 monoclonal antibody frequently used for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis. In addition, rituximab has recently been increasingly used as an off-label treatment in a number of inflammatory and systemic autoimmune diseases. It is advised that rituximab infusion may cause infusion reactions and adverse cardiac effects including arrhythmia and angina, especially in patients with prior history of cardiovascular diseases. However, its detailed cardiotoxicity profile and effects on cardiac function were not well described. We report a 51-year-old man who developed non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. The patient experienced reduced cardiac functions within 48 hours after the initial infusion, which remained markedly reduced at 9-month follow-up. As the utility of rituximab expands, physicians must be aware of this serious cardiovascular adverse effect.

Original languageEnglish (US)
Pages (from-to)18-25
Number of pages8
JournalJournal of Renal Injury Prevention
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Membranous Glomerulonephritis
Cardiomyopathies
Therapeutics
B-Cell Chronic Lymphocytic Leukemia
Vasculitis
Non-Hodgkin's Lymphoma
Autoimmune Diseases
Cardiac Arrhythmias
Rheumatoid Arthritis
Cardiovascular Diseases
Monoclonal Antibodies
Rituximab
Physicians
Antibodies

Keywords

  • Adverse effect
  • Cardiomyopathy
  • Cardiovascular disease
  • Membranous nephropathy
  • Rituximab

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. / Cheungpasitporn, Wisit; Kopecky, Stephen L.; Specks, Ulrich; Bharucha, Kharmen; Fervenza, Fernando Custodio.

In: Journal of Renal Injury Prevention, Vol. 6, No. 1, 01.01.2017, p. 18-25.

Research output: Contribution to journalArticle

Cheungpasitporn, Wisit ; Kopecky, Stephen L. ; Specks, Ulrich ; Bharucha, Kharmen ; Fervenza, Fernando Custodio. / Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. In: Journal of Renal Injury Prevention. 2017 ; Vol. 6, No. 1. pp. 18-25.
@article{87c3569a59714d4c966f8b6ebabde5f3,
title = "Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy",
abstract = "Rituximab is an anti-CD20 monoclonal antibody frequently used for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis. In addition, rituximab has recently been increasingly used as an off-label treatment in a number of inflammatory and systemic autoimmune diseases. It is advised that rituximab infusion may cause infusion reactions and adverse cardiac effects including arrhythmia and angina, especially in patients with prior history of cardiovascular diseases. However, its detailed cardiotoxicity profile and effects on cardiac function were not well described. We report a 51-year-old man who developed non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. The patient experienced reduced cardiac functions within 48 hours after the initial infusion, which remained markedly reduced at 9-month follow-up. As the utility of rituximab expands, physicians must be aware of this serious cardiovascular adverse effect.",
keywords = "Adverse effect, Cardiomyopathy, Cardiovascular disease, Membranous nephropathy, Rituximab",
author = "Wisit Cheungpasitporn and Kopecky, {Stephen L.} and Ulrich Specks and Kharmen Bharucha and Fervenza, {Fernando Custodio}",
year = "2017",
month = "1",
day = "1",
doi = "10.15171/jrip.2017.04",
language = "English (US)",
volume = "6",
pages = "18--25",
journal = "Journal of Renal Injury Prevention",
issn = "2345-2781",
publisher = "Nickan Research Institute",
number = "1",

}

TY - JOUR

T1 - Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy

AU - Cheungpasitporn, Wisit

AU - Kopecky, Stephen L.

AU - Specks, Ulrich

AU - Bharucha, Kharmen

AU - Fervenza, Fernando Custodio

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Rituximab is an anti-CD20 monoclonal antibody frequently used for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis. In addition, rituximab has recently been increasingly used as an off-label treatment in a number of inflammatory and systemic autoimmune diseases. It is advised that rituximab infusion may cause infusion reactions and adverse cardiac effects including arrhythmia and angina, especially in patients with prior history of cardiovascular diseases. However, its detailed cardiotoxicity profile and effects on cardiac function were not well described. We report a 51-year-old man who developed non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. The patient experienced reduced cardiac functions within 48 hours after the initial infusion, which remained markedly reduced at 9-month follow-up. As the utility of rituximab expands, physicians must be aware of this serious cardiovascular adverse effect.

AB - Rituximab is an anti-CD20 monoclonal antibody frequently used for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis. In addition, rituximab has recently been increasingly used as an off-label treatment in a number of inflammatory and systemic autoimmune diseases. It is advised that rituximab infusion may cause infusion reactions and adverse cardiac effects including arrhythmia and angina, especially in patients with prior history of cardiovascular diseases. However, its detailed cardiotoxicity profile and effects on cardiac function were not well described. We report a 51-year-old man who developed non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. The patient experienced reduced cardiac functions within 48 hours after the initial infusion, which remained markedly reduced at 9-month follow-up. As the utility of rituximab expands, physicians must be aware of this serious cardiovascular adverse effect.

KW - Adverse effect

KW - Cardiomyopathy

KW - Cardiovascular disease

KW - Membranous nephropathy

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85040672073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040672073&partnerID=8YFLogxK

U2 - 10.15171/jrip.2017.04

DO - 10.15171/jrip.2017.04

M3 - Article

AN - SCOPUS:85040672073

VL - 6

SP - 18

EP - 25

JO - Journal of Renal Injury Prevention

JF - Journal of Renal Injury Prevention

SN - 2345-2781

IS - 1

ER -